NCT04354766

COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2

Generation of Human Monoclonal Antibodies Neutralizing SARS-Cov-2 From B Cells of Convalescent Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Rationale : The emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) threatens public health. To date, there are no effective drug option to prevent the infection, nor therapeutics for controlling the deadly COVID-19. However, the majority of patients infected with SARS-Cov-2 eliminate the virus by mounting a protective antiviral immune response, associated in particular with the production of neutralizing antibodies. Neutralizing antibodies could be of particular interest for therapeutic purposes, but also for preventive applications, to protect people who have never been in contact with the virus, or immunocompromised patients. The objectives of this study are : * To generate human monoclonal antibodies neutralizing SARS-Cov-2 from immortalized B cells of convalescent patients. * To compare the serological profiles between convalescent patients that develop mild or uncomplicated illness and convalescent patients that develop a more severe disease, that required hospitalization and oxygen support. * To compare for each patient the neutralizing efficiency of plasma to the neutralizing capacities of the monoclonal antibodies generated with immortalized B cells.

Conditions

• COVID

Interventions

Type	Name	Description
OTHER	Blood sample	This study will require a blood sample (4 ACD tubes, 20 ml) at one time.

Timeline

• Start date: 2020-04-29
• Primary completion: 2020-05-18
• Completion: 2020-05-18
• First posted: 2020-04-21
• Last updated: 2021-06-18

Locations

1 site across 1 country: France